论文部分内容阅读
本文报告美国癌与急性白血病B 组用DDP 治疗晚期恶性淋巴瘤27例的Ⅱ期实验研究结果。其适应症为:①病理证实为晚期恶性淋巴瘤;②用标准的治疗方法无效者;③有可测量的肿瘤;④粒细胞计数<2000/mm~3、血小板计数<100,000/mm~3、肌酐<1.5 mg/dl、胆红素<2 mg/dl、转氨酶<120 IU、周围血淋巴细胞低于30%以及骨髓中淋巴细胞低于30%。给药方法为70 mg/M~2,静脉灌注,每3周给药一次。注射时间在20～60分钟。要求治疗前在无利尿剂情况下连续4小时,每小时能泌尿100ml。给药
This article reports the results of a phase II study of 27 patients with advanced malignant lymphoma treated with DDP in the United States cancer and acute leukemia group B. The indications are: 1 pathologically confirmed as late malignant lymphoma; 2 using standard treatment ineffective; 3 with measurable tumor; 4 cell count <2000/mm~3, platelet count < 100,000/mm~3, Creatinine <1.5 mg/dl, bilirubin <2 mg/dl, transaminase <120 IU, peripheral blood lymphocytes below 30%, and lymphocytes in the bone marrow below 30%. The method of administration was 70 mg/M~2, intravenous infusion, once every 3 weeks. Injection time is 20 to 60 minutes. Before treatment, in the absence of diuretics for 4 hours, urinary excretion of 100 ml per hour was required. Dosing